BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nutra Pharma Corp. (NPHC) Faces Involuntary Bankruptcy


9/5/2012 8:23:46 AM

South Florida Business Journal by Paul Brinkmann, Reporter

A group of creditors for a Coral Springs-based biotech company, Nutra Pharma Corp., is asking a judge to put the company into Chapter 7 bankruptcy.

Nutra Pharma (Pink Sheets: NPHC) has focused mainly on marketing a pain reliever product called Nyloxin, which contains ingredients derived from cobra venom.

Bankruptcy attorneys on Friday filed an involuntary petition to push the company into bankruptcy. Five claims were listed on the bankruptcy, four of which were from officers or employees of a Nutra Pharma subsidiary who claimed they are owed salary.

Neither the company nor the bankruptcy attorney, Philip Landau of Boca Raton-based Shraiberg, Ferrara & Landau, could be reached by deadline for comment.

Nutra Pharma had warned shareholders this summer that lack of funds was restricting its business scope and caused it to be delisted from the over-the-counter trading platform.

The claims are as follows:

Paul Reid, CEO of the company’s subsidiary ReceptoPharm, Inc. $459,920

Marc Proulx, former vice president of ReceptoPharm, $13,187

Lawrence Raymond, chief science officer of ReceptoPharm, $342,954

John David Schmidt, $153,875

MLB Marketing Corp., $21,000




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES